Convatec launches $200 million buyback as second-half margin outlook improves

Convatec launches $200 million buyback as second-half margin outlook improves
Convatec $200M buyback boost

Convatec is signaling stronger profitability for the second half of 2026 as demand rises for its infusion care products. The UK medical products maker also tightens its annual organic revenue growth range while keeping its expectation for double-digit earnings growth.

Highlights

  • Convatec announces a $200 million share buyback program to be completed by end of 2026 amid improved second-half margin outlook.
  • Second-half organic revenue growth forecast excluding InnovaMatrix is set at 6% to 8%, with full-year guidance tightened to 5.5% to 6.5%.
  • For the six months ended June 30, Convatec reports revenue of $1.23 billion, up 1.8% at constant currency, with organic revenue excluding InnovaMatrix rising 5%.

Second-half growth outlook and capital return

As reported by Reuters, Convatec says its second-half operating margin is expected to be materially higher than in the first half, with growth set to accelerate in the second half of 2026.

The company forecasts 6% to 8% organic revenue growth excluding InnovaMatrix for the second half, driven by stronger performance in its infusion care unit. Convatec also narrows its full-year organic revenue growth forecast excluding InnovaMatrix to 5.5% to 6.5%, from the earlier 5% to 7%, and still expects double-digit earnings growth.

Convatec also announces a new $200 million share buyback programme, which is due to be completed by the end of 2026. It says it remains on track to launch eight new chronic-care products across 2026 and 2027, including six this year.

Infusion care demand supports group performance

Infusion Care accounts for about 19% of group revenue and supplies disposable infusion sets used with insulin pumps for diabetes, as well as continuous infusion therapies for conditions including Parkinson's disease.

For the six months ended June 30, revenue reaches $1.23 billion, up 1.8% at constant currency, while organic revenue excluding InnovaMatrix grows 5%. Convatec also makes catheters and drug delivery systems, and the stronger infusion care trend points to support for its broader chronic-care portfolio.

In our earlier article on HSBC’s stronger second-quarter earnings and updated 2026 outlook, we covered how the bank beat profit expectations on solid wealth management and insurance performance in Hong Kong. We also noted HSBC kept its medium-term profitability targets and paired the upbeat guidance with a $1 billion share buyback, alongside ongoing restructuring and asset disposals aimed at improving capital efficiency.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.